Vivid Genomics, Inc. to present at Biotech Showcase(TM) 2019 in San Francisco

SAN DIEGO, Jan. 2, 2019 /PRNewswire/ — Vivid Genomics, Inc., a company focused on providing tools to improve clinical trials outcomes in neurodegenerative disease by identifying the right patients, today announced that it will present at Biotech Showcase™ 2019, to be held January 7–9, during the most important week in healthcare at the Hilton San Francisco Union Square. Dr. Julie Collens, CEO of Vivid Genomics, will be giving a presentation and meeting with investors.

Event: Seed Showcase 2019
Date: Wednesday, January 9th, 2019
Presentation Time: 4pm PST
Location: Hilton San Francisco Union Square Hotel, 333 O’Farrell Street, San Francisco, CA
Room: Franciscan B (Ballroom Level)

“We are pleased and honored to be selected as one of ten seed-stage companies to present during the Seed Showcase as part of the Biotech Showcase™,” said Julie Collens, CEO of Vivid Genomics.  The event takes place during the course of one of the industry’s largest annual healthcare investor conferences, J.P. Morgan Annual Healthcare Conference.

For early-stage investors attending Biotech Showcase who wish to schedule a meeting with Vivid Genomics leadership, please contact info@vividgenomics.com.

ABOUT VIVID GENOMICS
Vivid Genomics is dedicated to helping pharmaceutical companies improve the probability of clinical trial success by identifying, enrolling, and stratifying the right patients.  Using expertise in genomics, machine learning, and neurodegenerative disease biology, we develop genetic-based tests to identify patient variation, providing insight to inform clinical trial design to reduce biases that impact clinical trial outcomes. 

Contacts
Vivid Genomics, Inc.
JLABS
3210 Merryfield Row
San Diego, CA 92121
info@vividgenomics.com 
Follow Vivid Genomics, Inc. on Twitter at @Vgenomics

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/vivid-genomics-inc-to-present-at-biotech-showcase-2019-in-san-francisco-300771904.html

SOURCE Vivid Genomics

Click to view original post